Enspryng Phase III results released by Roche (SIX: RO, ROG; OTCQX: RHHBY) signal a historic turning point for patients living with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). The pivotal Phase III METEOROID study met its primary endpoint, demonstrating that satralizumab (Enspryng) significantly reduced the risk of relapses by 68% compared to placebo in adults and adolescents.
MOGAD is a rare, debilitating neuroinflammatory condition that causes the immune system to attack the protective myelin sheath around nerves. Until these findings, there were no FDA-approved treatments specifically indicated for MOGAD, leaving patients to rely on off-label therapies.
Unpacking the Enspryng Phase III Results
The Enspryng Phase III results from the METEOROID trial showcased high levels of efficacy across both primary and secondary objectives. The study included 188 participants who were randomized to receive either satralizumab or a placebo. Data indicated that 87% of patients treated with Enspryng remained relapse-free at the 48-week mark, compared to just 67% in the control group.
These Enspryng Phase III results underscore the critical role of IL-6 inhibition in managing MOGAD. We are encouraged by the 68% risk reduction, which could provide much-needed stability for patients who live in constant fear of their next attack.
Dr. Levi Garraway, Roche’s Chief Medical Officer
Learn More: Roche’s Gazyva/Gazyvaro Gets U.S. FDA Approval for Lupus Nephritis Treatment
Key Efficacy Metrics (METEOROID Study)
| Clinical Endpoint | Enspryng (Satralizumab) | Placebo | Statistical Significance |
| Relapse Risk Reduction | 68% Lower | Reference | p = 0.0025 |
| Relapse-Free at 48 Weeks | 87% | 67% | Significant |
| Annualized Relapse Rate (ARR) | 0.12 | 0.38 | p = 0.0030 |
| Risk of New MRI Lesions | 79% Reduction | Reference | p < 0.001 |
This news article summarizes the breakthrough results from the Phase III METEOROID trial for Roche’s Enspryng in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
AstraZeneca Q3 2026 Results: Total Revenue Rises 7% to $46.9bn as Oncology Leads Growth and FY2026 Guidance Holds
AstraZeneca Q3 2026 results, published 30 October 2026, show nine-month revenue of $46.9bn, up 7% at CER, and Core EPS of $8.00, up 14%. Oncology […]
AbbVie Q3 2026 Results: Skyrizi, Rinvoq and Vraylar Drive $17.404 Billion Revenue as EPS Guidance Rises
AbbVie Q3 2026 Results show $17.404B revenue, led by Skyrizi and Rinvoq, with higher 2026 EPS guidance and a 5.2% dividend increase. […]
Merck Daejeon Bioprocessing Center Opens With €300 Million Investment to Expand Asia-Pacific Biologics Supply
The Merck Daejeon bioprocessing center opened on 29 October 2026 with a €300 million-plus investment, adding cell culture media, process liquids and sterile sampling capacity […]
Safety Profile Observed in Enspryng Phase III Results
Safety is a paramount concern for long-term autoimmune management. The Enspryng Phase III results confirmed that the safety and tolerability profile of satralizumab in MOGAD is consistent with its established profile in Neuromyelitis Optica Spectrum Disorder (NMOSD). The most frequently reported adverse events were mild to moderate, primarily consisting of injection-related reactions and upper respiratory tract infections.
| Adverse Event | Enspryng (%) | Placebo (%) |
| Injection-Related Reactions | 16% | 12% |
| Nasopharyngitis | 11% | 10% |
| Headache | 9% | 8% |
| Arthralgia | 7% | 5% |
| Urinary Tract Infection | 6% | 6% |
Clinical Implications and Next Steps
Following the successful validation of the Enspryng Phase III results, Roche intends to submit the data to global regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). If approved, Enspryng would become the first-ever therapy specifically indicated for MOGAD, addressing a massive unmet medical need.
